Share Name Share Symbol Market Type Share ISIN Share Description
Beximco Pharma LSE:BXP London Ordinary Share US0885792061 GDR (EACH REPR 1 ORD BDT10)(REGS)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +3.00p +4.96% 63.50p 62.00p 65.00p 63.50p 60.50p 60.50p 41,596.00 09:04:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 112.5 20.3 4.4 12.5 245.27

Beximco Pharma Share Discussion Threads

Showing 1426 to 1447 of 1450 messages
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
DateSubjectAuthorDiscuss
17/2/2017
13:39
Usually get a move down followed by a big move up..
zcaprd7
13/2/2017
11:50
:o) just a matter of time until dhaka goes for a blue sky rise... big rise to come over the next two years... 'sittin and waitin' GLA
greg the grinch
13/2/2017
10:46
on big volume as well
deltrotter
13/2/2017
10:45
fast reaching a 2 year high in Dhaka.
rogash
09/2/2017
10:13
I think glaxo warned on the threat from generics for 2017, yesterday?
zcaprd7
03/2/2017
13:14
The incentive for US companies to take on a 'Global market' generics manufacturer like Beximco, with their much lower wage structure and "manufacturing facilities in place" isn't that great that it will pose any significant threat. As well as US wage levels, any manufacturing plant will have to pass FDA, and that's going to take a large amount of time, as well as money. I can't see it happening if Trump is half serious about getting drug costs down, and what I see as more likely is that Beximco gets more approvals for generic rivals to currently high-priced prescription drugs.
outsizeclothes.com
31/1/2017
19:40
At the end of the day if Trump makes the US uncompetitive then all other manufacturers will benefit . . . .so lets pray for that
ginko3
31/1/2017
16:38
Also if he does allow the US co's to bump up their prices to other countries then BXP products are even more attractive to all non-US countries.
greg the grinch
31/1/2017
16:34
Seems like you wont be at the BXP £1 party :o) htTp://www.cnbc.com/2017/01/31/trump-tells-drugmakers-he-wants-them-to-manufacture-in-the-us.html 'competition is the key' also he wants US drug makers to bring back their outsourcing... BXP are not that. Some of the things he mentions are not going to happen at any scale... US co's will not be able to massively bump up prices to foreign countries... etc I'm off to do some 'sittin and waitin' GLA
greg the grinch
31/1/2017
15:04
I've now sold Trump meets with top drugmakers, calls on pharmaceutical industry to boost U.S. production, lower prices hxxp://reut.rs/2kLESwY
panic investor
28/1/2017
18:09
Anybody worried about American imports ? Just raising the subject as America first seems to be moving forward
panic investor
27/1/2017
12:29
Those results are the trickle before the torrent. :o) US sales set to rise in a big way. Share was too cheap... still is... should be x2 DYOR :o) GLA
greg the grinch
27/1/2017
12:25
Super breakout today,but why so much ,interim results seemed to be inline and nothing new and exciting. Still catching up the discount to the price in Bangladesh?
nfs
27/1/2017
10:54
Only recently on my radar and bought a few a couple of weeks ago but this does seem to be a solid, professionally run company and will start to move cash from less well performing stock in my portfolio into BXP.
ginko3
27/1/2017
09:24
Sold this am but have decided to buy back in, as this is rightly a sit and ride now. As many have said more to c0me. All buys ticking up.
mustau
27/1/2017
09:07
Excellent results from a super little company. What a lot of growth prospects they have. Well done them, and great for the Bangladeshi people.
deltrotter
27/1/2017
08:08
Moving up.
someuwin
27/1/2017
07:19
BEXIMCO PHARMACEUTICALS LTD. 27 January, 2017 Half Year Results 2016-17 Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its un-audited financial results for the six months ended 31 December, 2016. Financial highlights Half year financial highlights -- Net sales increased by 13.6% to Bangladesh Taka ("BDT") 7,630.6 m / GBP79.7 m (2015: BDT 6,716.3m / GBP58.0m) -- Profit after tax increased by 17.8% to BDT 1,112.9m / GBP11.6m (H1 2015: BDT 945.1m/ GBP8.2m) Second quarter financial highlights -- Net sales increased 16.0% to BDT 3,865.0m / GBP40.4m (2015: BDT 3,330.6m / GBP28.8m) -- Profit after tax increased 14.0 % to BDT 598.0m / GBP6.2m (2015: BDT 524.5 m / GBP4.5m) Operational highlights -- A total of eight new products (five generics) launched in the domestic market o Three of which were launched for the first time in Bangladesh (Voglibose, Cholecalciferol and Dienogest) -- Commenced US export of Carvedilol, a prescription drug for treating hypertension, in August o The first Bangladeshi pharmaceutical company to export pharmaceutical products to the US -- Received approval for two more products, Sotalol and Metformin Hydrochloride, from US FDA in November and December, respectively -- Medicine Patent Pool (MPP) of the UN granted sub-license to Beximco Pharma to manufacture Bristol-Myers Squibb's new hepatitis C drug, Daclatasvir -- Received product approval from Health Canada for Olopatadine eye drop o Another first time achievement for a Bangladeshi pharmaceutical company -- Two ophthalmic products registered in Australia -- Commenced export to Panama, Zimbabwe, Mali and Guinea Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented: "With the formal launch of Carvedilol in August, Beximco Pharma became the first Bangladeshi pharmaceutical company to export a prescription drug to US. In addition, we received approval for two more products from US FDA during the period. We continued to perform well in the domestic market, posting a sales growth of 14.4% over the corresponding period in 2015. We are confident that we will be able to maintain our growth momentum by achieving our operational and financial targets for the full year."
someuwin
26/1/2017
12:30
someuwin (post 77)- I echo your sentiments. The FDA have recently been revoking the licence of many Indian pharmaceutical companies to sell generics/API in the US, you would imagine this trend to continue under Trump. For Beximco to actually receive approval of 3 of their products during this period is certainly swimming against the tide and does indeed tell you something about the quality of their business.
firtashia
26/1/2017
11:18
:o) That's the spike I have been waiting for.... it has more to go... :o) I am holding for years as this will multibag. GLA
greg the grinch
26/1/2017
10:50
Irrespective of actual sales to the US (which I believe will ramp up quickly), the game changer here is the fact that they have received FDA approval for not just one, but three seperate drugs: Blood pressure, cardiovascular and diabetes. (all approvals granted in the last 12 months). Its a great testament to their design and production quality. And will aid sales of all their products worldwide.
someuwin
26/1/2017
10:33
Actually the US products only account for a very small part of revenue. What Trump does doesn't really make much difference to them, especially since they are doing so well in the Far East. 59p UK against 91.1p Dhaka equivalent is ridiculous. j
jswjsw
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170219 14:23:19